Effects of arginine vasopressin (AVP) infusions on circulating concentrations of platelet AVP, factor VIII: C and von Willebrand factor.
To study the possible role of arginine vasopressin (AVP) in the control of haemostasis AVP infusions at 3 doses (0.1, 0.2 and 0.3 mU/kg/min) were performed in 6 male volunteers. Both plasma and platelet AVP concentrations rose in a dose-related manner. At doses of 0.2 and 0.3 mU/kg/min there was an increase in the plasma concentrations of both plasma Factor VIII and von Willebrand factor. The data support the hypothesis that AVP, by interacting with platelets and stimulating factor VIII and von Willebrand factor release, plays a role in the control of haemostasis.
D000328:Adult; D001127:Arginine Vasopressin / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D005169:Factor VIII / Q000378:metabolism*; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D014841:von Willebrand Factor / Q000378:metabolism*
D014841:von Willebrand Factor; D001127:Arginine Vasopressin; D005169:Factor VIII